Showing results (1131-1140 of 1,351) with videos related to

Sort By:
Pageof 136
Environmental Toxicology and Chemistry|September 5, 2018
Toward harmonizing ecotoxicity characterization in life cycle impact assessmentPeter Fantke, Nicoló Aurisano, Jane Bare, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|November 1, 2011
Comparison of gamma-ray coincidence and low-background gamma-ray singles spectrometryJ Konki, P T Greenlees, U Jakobsson, et al.
Human Molecular Genetics|December 5, 2017
DCC/NTN1 complex mutations in patients with congenital hypogonadotropic hypogonadism impair GnRH neuron developmentJustine Bouilly, Andrea Messina, Georgios Papadakis, et al.
Molecular & Cellular Proteomics : MCP|January 11, 2026
Higher-Throughput Proteome Profiling Enabled by Parallelized Pre-Accumulation and Optimized Ion Processing in the Orbitrap Astral Zoom Mass SpectrometerUlises H Guzman, Martin Rykar, Ivo A Hendriks, et al.
Lancet (London, England)|June 28, 2012
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Jean-Jacques Grob, Lev V Demidov, et al.
Physical Review Letters|March 14, 2003
New shape isomer in the self-conjugate nucleus 72KrE Bouchez, I Matea, W Korten, et al.
Lancet (London, England)|May 18, 2020
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trialLisa Zimmer, Elisabeth Livingstone, Jessica C Hassel, et al.
Lancet (London, England)|September 13, 2022
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trialElisabeth Livingstone, Lisa Zimmer, Jessica C Hassel, et al.
The New England Journal of Medicine|June 7, 2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanomaCaroline Robert, Luc Thomas, Igor Bondarenko, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2015
A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanomaE M Hersh, M Del Vecchio, M P Brown, et al.
Pageof 136